Article
The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
Oncotarget - 31 Jan 2017
You Liangshun, Liu Hui, Huang Jian, Xie Wanzhuo, Wei Jueying, Ye Xiujin, Qian Wenbin
Abstract excerpt
Chronic myeloid leukemia (CML) is a clonal malignant disease caused by the expression of BCR/ABL. MDM2 (human homolog of the murine double minute-2) inhibitors such as Nutlin-3 have been shown to induce apoptosis in a p53-dependent manner in CML cells and sensitize cells to Imatinib. Here, we demonstrate that JNJ-26854165, an inhibitor of MDM2, inhibits proliferation and triggers cell death in a p53-independent...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.